Neurofit Unveils Multiple Sclerosis Imaging Analysis Software "Neurofit AQUA MS"

Neurofit, an artificial intelligence (AI) company specializing in the diagnosis and treatment of brain diseases, announced on the 5th that it will participate in the ACTRIMS Forum 2026, which will be held in San Diego, United States, from February 5 to 7.

Image of Neurofit participating in the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2026. Neurofit

원본보기 아이콘

During the event, Neurofit will showcase Neurofit AQUA MS, a quantitative imaging analysis software for multiple sclerosis. It is a software solution that adds multiple sclerosis analysis capabilities to the brain imaging analysis solution Neurofit AQUA. The software quantitatively analyzes structural changes and the degree of atrophy progression in the brains of patients with multiple sclerosis.

Neurofit AQUA MS enables brain structure analysis and follow-up not only with T1 images but also using only T2-FLAIR images. This allows for assessment of disease progression even when obtaining T1 images is difficult, which, according to the company, makes the product highly useful for patients who face constraints related to examination costs or imaging environments. The product received 510(k) clearance, a premarket notification process, from the U.S. Food and Drug Administration in October 2024.

Through its participation in this forum, Neurofit plans to identify clinical trends in multiple sclerosis in North America and discuss practical clinical application strategies through meetings with local neurologists. The company also intends to pursue an expansion of product supply, focusing on medical institutions in North America.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.